Cingulate Inc.

NasdaqCM CING

Cingulate Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024

Cingulate Inc. EPS (Diluted) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Cingulate Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3,599.97, a -915.08% change year over year.
Cingulate Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -354.65, a 13.19% change year over year.
Cingulate Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -408.52.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: CING

Cingulate Inc.

CEO	Dr. Shane J. Schaffer Pharm.D.
IPO Date	Dec. 8, 2021
Location	United States
Headquarters	1901 West 47th Place
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Key trends

Past 5 years